NASDAQ: SSIISs Innovations International Inc Stock
$4.76+0.30 (+6.73%)
Updated Mar 16, 2026
SSII Price
$4.76
Fair Value Price
N/A
Market Cap
$925.14M
52 Week Low
$3.02
52 Week High
$22.42
P/E
-79.33x
P/B
24.21x
P/S
25.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$42.48M
Earnings
-$12.13M
Gross Margin
46%
Operating Margin
-16.6%
Profit Margin
-28.5%
Debt to Equity
0.94
Operating Cash Flow
-$19M
Beta
0.36
Next Earnings
May 14, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SSII Overview
SS Innovations International, Inc. develops surgical robotic systems. It also develops SSI Mantra, a surgical robotic system; SSI Mudra, a range of surgical instruments that supports in surgical procedures, including robotic cardiac surgery; SSI Maya, a robotic surgery platform; and OMNI 3D HD provides live 3D HD view of the surgical field in robotic surgery operating room. The company is based in Fort Lauderdale, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SSII's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
SSII
Ranked#79 of 103
Ranked#79 of 103
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.87 | A | |
| $9.78 | A | |
| $27.30 | A |
Be the first to know about important SSII news, forecast changes, insider trades & much more!
SSII News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SSII scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SSII is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SSII is poor value based on its book value relative to its share price (24.21x), compared to the US Medical Devices industry average (3.43x)
P/B vs Industry Valuation
SSII is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SSII due diligence checks available for Premium users.
Valuation
SSII fair value
Fair Value of SSII stock based on Discounted Cash Flow (DCF)
Price
$4.76
Fair Value
-$0.90
Undervalued by
629.05%
SSII is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SSII price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-79.33x
Industry
26.43x
Market
32.08x
SSII price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
24.21x
Industry
3.43x
SSII is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SSII's financial health
Profit margin
Revenue
$14.5M
Net Income
-$2.5M
Profit Margin
-17%
SSII's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SSII's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$74.2M
Liabilities
$36.0M
Debt to equity
0.94
SSII's short-term assets ($48.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SSII's short-term assets ($48.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SSII's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
-$1.7M
Financing
$1.4M
SSII's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SSII vs Medical Device Stocks
Ss Innovations International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.